The CANTOS (for “canakinumab anti-inflammatory thrombosis outcome study”) trial evaluated the effect of treatment with canakinumab, an anti-IL-1β neutralizing monoclonal IgG1 antibody, in patients with a history of myocardial infarction and high circulating levels of C-reactive protein (CRP). Here, CRP is linked to myocardial infarction.